Pfizer Inc. (NYSE: PFE) is scheduled to provide its full-year 2026 financial guidance on Tuesday, with Bank of America Securities expecting the company's growth profile to closely resemble conditions ...

Pfizer shares are trading in the mid-$20s as investors grapple with a critical question: is this battered pharmaceutical giant destined to remain stuck in neutral, or does its aggressive push into ...

Yesterday, the Pharma giant Pfizer Inc. (PFE) took the unusual step of not only providing its full-year 2025 revenue and earnings numbers but also providing precise guidance for full-year 2026.

Pfizer’s revenue soared to record heights a few years ago thanks to its coronavirus products, but growth has since slowed. The company is counting on new products, and a focus on oncology, to drive ...